Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers
- Open Access
- 02.05.2024
- Correction
Erschienen in:
Correction: Clinical Pharmacokinetics https://doi.org/10.1007/s40262-024-01365-4
In Table 1 of this article, the column head “DTG + F/TAT (test C)” should have read “DTG + F/TAF (test C)” and the column head “F/TAT (reference A)” should have read “F/TAF (reference A)”. The corrected table is given below.
Table 1
PK parameters of DTG, TAF, TFV, and FTC in each treatment (test versus reference)
PK parameter | DTG + F/TAF (test C) | DTG (reference B) | GLSM ratio (90% CI) |
|---|---|---|---|
DTG | |||
AUC0–∞ (h*mg/L) | 40.71 (30) | 40.18 (27) | 1.02 (0.94–1.10) |
Cmax (mg/L) | 2.69 (22) | 2.35 (24) | 1.16 (1.10–1.23) |
Tmax (h) | 0.75 (0.5–1.0) | 1.0 (1.0–2.0) | |
T½ (h) | 12.97 (17) | 13.38 (15) |
PK parameter | DTG + F/TAF (test C) | F/TAF (reference A) | GLSM ratio (90% CI) |
|---|---|---|---|
TAF | |||
AUC0–∞ (h*ng/mL) | 104.87 (57) | 115.75 (42) | 0.83 (0.62–1.11) |
Cmax (ng/mL) | 180.14 (44) | 204.95 (37) | 0.81 (0.65–1.01) |
Tmax (h) | 0.3 (0.3–0.3) | 0.3 (0.2–0.3) | |
T½ (h) | 0.35 (21) | 0.33 (24) | |
TFV | |||
AUC0–last (h*ng/mL) | 89.19 (54) | 98.04 (32) | 0.84 (0.70–1.01) |
Cmax (ng/mL) | 7.03 (29) | 6.34 (24) | 1.06 (0.92–1.23) |
Tmax (h) | 0.75 (0.3–0.9) | 0.75 (0.6–1.0) | |
T½ (h) | 32.44 (36) | 36.73 (33) | |
FTC | |||
AUC0–∞ (h*mg/L) | 7.52 (15) | 7.80 (20) | 0.97 (0.92–1.02) |
Cmax (mg/L) | 1.49 (20) | 1.44 (25) | 1.05 (0.94–1.17) |
Tmax (h) | 0.75 (0.5–1.0) | 0.78 (0.75–1.5) | |
T½ (h) | 7.41 (22) | 8.14 (34) | |
Anzeige
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.